Back

Treatment of non-alcoholic steatohepatitis with recombinant Orosomucoid 2, an acute phase protein that attenuates the Erk1/2-PPARγ-Cd36 signaling pathway

Li, L.; Sun, H.; Chen, J.; Ding, C.; Yang, X.; Han, H.; Sun, Q.

2022-10-23 molecular biology
10.1101/2022.10.22.513320 bioRxiv
Show abstract

Therapeutic administration of recombinant proteins has been used for the treatment of various diseases in multiple studies. Herein, we investigated the function of the acute phase protein Orosomucoid 2 (Orm2), which is mainly secreted by hepatocytes, and evaluated its potential as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). We here revealed that a high expression of Orm2 protected mice from high-fat diet (HFD)-induced obesity. The pharmacological administration of recombinant ORM2 protein attenuated hepatic steatosis, inflammation, hepatocyte injury, and fibrosis in mouse livers, which suffered NAFLD and NASH under dietary challenge conditions. Orm2 knockout mice spontaneously underwent obese after 16 weeks under normal diet. Orm2 deficiency exacerbated HFD-induced steatosis, steatohepatitis, and fibrosis in mice. Mechanistically, the deletion of Orm2 led to the activation of the Erk1/2-PPAR{gamma}-Cd36 signaling pathway, which in turn increased fatty acid uptake and absorption in hepatocytes and mice. Collectively, our results provide Orm2 is an essential factor for preventing NASH and associated NAFLD under obesity.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 0.7%
31.6%
Similar papers in this journal
2
Cell Discovery
○ 57 papers in training set
Top 0.1%
5.3%
Similar papers in this journal
3
Journal of Hepatology
○ 21 papers in training set
Top 0.1%
4.4%
Similar papers in this journal
4
Nature Communications
○ 5641 papers in training set
Top 33%
3.5%
Similar papers in this journal
5
Cell Reports
○ 1498 papers in training set
Top 14%
2.7%
6
Protein & Cell
◐ 25 papers in training set
Top 0.1%
2.7%
50% of probability mass above
7
iScience
○ 1154 papers in training set
Top 9%
2.7%
Similar papers in this journal
8
Acta Biochimica et Biophysica Sinica
● 23 papers in training set
Top 0.2%
2.4%
9
Advanced Science
○ 286 papers in training set
Top 3%
2.2%
10
The FASEB Journal
○ 194 papers in training set
Top 2%
1.9%
11
Molecular Medicine
○ 11 papers in training set
Top 0.1%
1.8%
12
Science Advances
● 1243 papers in training set
Top 20%
1.7%
13
Metabolism
○ 15 papers in training set
Top 0.2%
1.5%
14
Acta Pharmaceutica Sinica B
○ 11 papers in training set
Top 0.1%
1.5%
15
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
○ 26 papers in training set
Top 0.3%
1.5%
16
eBioMedicine
○ 183 papers in training set
Top 3%
1.5%
17
Scientific Reports
○ 3612 papers in training set
Top 62%
1.1%
18
Communications Biology
○ 993 papers in training set
Top 20%
1.1%
19
Hepatology Communications
○ 22 papers in training set
Top 0.3%
1.1%
20
Cell Death & Differentiation
○ 48 papers in training set
Top 0.9%
1.1%
21
Arteriosclerosis, Thrombosis, and Vascular Biology
○ 71 papers in training set
Top 1%
1.0%
22
Molecular Therapy - Nucleic Acids
○ 25 papers in training set
Top 0.6%
1.0%
23
PLOS ONE
● 5266 papers in training set
Top 56%
1.0%
24
Molecular Metabolism
○ 112 papers in training set
Top 2%
0.9%
25
Science Bulletin
○ 21 papers in training set
Top 0.4%
0.9%
26
International Journal of Molecular Sciences
○ 494 papers in training set
Top 14%
0.9%
27
Cell Research
○ 51 papers in training set
Top 1%
0.9%
28
National Science Review
◐ 21 papers in training set
Top 0.2%
0.9%
29
Human Molecular Genetics
◐ 141 papers in training set
Top 3%
0.6%
30
Cellular and Molecular Gastroenterology and Hepatology
○ 46 papers in training set
Top 1%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.